UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Bayer

B

Bayer

Cardiovascular & MetabolicLeverkusen, Germany
Visit Website

About Bayer

Bayer is one of the oldest and most globally recognised life sciences companies in the world, founded in Barmen, Germany in 1863 and responsible for introducing aspirin to modern medicine. Today the company operates across more than 100 countries, employing tens of thousands of people and generating revenues in the tens of billions of euros annually, with its shares listed on the Frankfurt Stock Exchange under the ticker BAYN.

Pharmaceuticals Division

Bayer's pharmaceuticals business focuses on four core therapeutic areas: cardiovascular disease, oncology, gynaecology, and ophthalmology. The company's cardiovascular portfolio is among the most recognised in the industry, anchored by Xarelto (rivaroxaban), one of the world's most widely prescribed oral anticoagulants. In oncology, Bayer has built a substantial presence in targeted therapies, including treatments for renal cell carcinoma and thyroid cancer. The division also holds a strong position in women's health, with a broad contraception and fertility product range distributed globally.

Crop Science & Consumer Health

Beyond pharmaceuticals, Bayer operates one of the world's largest crop science divisions, a segment significantly expanded following the acquisition of Monsanto in 2018. This business covers herbicides, fungicides, insecticides, and seeds, making Bayer a central player in global agricultural supply chains. The company's consumer health division, which markets established brands in pain relief, dermatology, nutritional supplements, and allergy care, was partially divested through a strategic review, reflecting Bayer's continued focus on its prescription and crop science core.

Bayer's research and development investment spans biologics, cell and gene therapy, and radiopharmaceuticals, with the company actively expanding its pipeline through both internal programmes and external partnerships and acquisitions. Its global headquarters remain in Leverkusen, Germany, where the company was formally established.

Further information is available at bayer.com.

Similar Companies

More in Cardiovascular & Metabolic

A

AstraZeneca UK

AstraZeneca is one of the world's largest biopharmaceutical companies, with its global headquarters at the Cambridge Biomedical Campus in England. Founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group of the United Kingdom, the company is listed on the London Stock Exchange (AZN) and on Nasdaq, and employs approximately 90,000 people across more than 100 countries. Cambridge functions not merely as a corporate address but as the centre of the company's worldwide research and early development capability, hosting thousands of scientists working across discovery biology, chemistry, and translational medicine. Therapy Areas and Pipeline The company's research strategy concentrates on three main therapy area clusters: oncology, cardiovascular, renal and metabolic disease (CVRM), and respiratory and immunology (R&I). Within oncology, AstraZeneca markets established medicines including osimertinib (Tagrisso), olaparib (Lynparza, developed with MSD), and durvalumab (Imfinzi). The CVRM portfolio includes dapagliflozin (Farxiga/Forxiga), which has received regulatory approvals across heart failure, chronic kidney disease, and type 2 diabetes indications. The respiratory franchise covers budesonide/formoterol combinations and the biologic tezepelumab (Tezspire, developed with Amgen) for severe asthma. UK Operations and Clinical Development AstraZeneca UK operates across the full pharmaceutical value chain: early and late-stage clinical trials, regulatory affairs, medical affairs, market access, and commercial operations serving the National Health Service. The UK site at Cambridge is complemented by manufacturing and biologics development capabilities at sites including Macclesfield. The company collaborates extensively with the Medical Research Council, Cancer Research UK, and NHS England, and was a prominent partner in the University of Oxford COVID-19 vaccine programme, through which AstraZeneca's Vaxzevria was manufactured and distributed globally at no profit during the pandemic period. AstraZeneca participates in hundreds of sponsored clinical studies in the United Kingdom at any given time, engaging NHS trusts, academic medical centres, and independent research sites. The organisation also operates a patient access programme infrastructure and maintains a dedicated UK medical information service for healthcare professionals. Further information is available at astrazeneca.co.uk.

View profile
V

Viatris

Born from the 2020 combination of Mylan and Pfizer's Upjohn division, Viatris operates as one of the world's largest generic and established medicines companies, serving patients across more than 165 countries with a portfolio spanning both off-patent generics and branded products. The company's founding premise was to bridge the gap between innovation and access, ensuring that essential medicines reach patients regardless of geography or economic circumstance. Portfolio Breadth and Therapeutic Reach Viatris maintains a catalogue of approximately 1,400 molecules covering a wide range of therapeutic areas, including cardiovascular disease, infectious disease, central nervous system conditions, oncology, immunology, and respiratory health. The company is recognised as a leading global supplier of antiretrovirals for HIV treatment, a position inherited in part from Mylan's longstanding role in global health programmes. Its branded medicines include well-known products such as Lipitor (atorvastatin) and EpiPen, alongside an extensive generics and complex generics pipeline. Global Manufacturing and Access Mission Headquartered in Canonsburg, Pennsylvania, USA, and incorporated in 2020, Viatris operates a substantial global manufacturing network with facilities across North America, Europe, and Asia. The company is publicly listed on the Nasdaq exchange under the ticker symbol VTRS. Its scale enables a dual mandate: competing commercially in mature markets while actively supplying low- and middle-income countries through tiered pricing and partnership agreements with international health bodies. Viatris has also pursued a strategic refocusing in recent years, divesting certain assets to concentrate resources on higher-value complex generics, biosimilars, and brand-name medicines. The biosimilars segment represents a growing area of investment, with the company working to commercialise alternatives to complex biologics across key markets. This evolution reflects a broader industry shift as the patent cliff for major biologics opens new competition opportunities for experienced generics manufacturers. Further information is available at viatris.com.

View profile
C

Covis Pharma

Covis Pharma built its model around acquiring and commercialising established, off-patent branded medicines that larger pharmaceutical companies no longer prioritise, giving those products renewed focus and commercial investment. Founded in 2011 and headquartered in Zug, Switzerland, the company operates internationally with a significant commercial presence across Europe and North America. The portfolio centres on specialty and hospital medicines, with particular depth in cardiovascular, respiratory, and women's health therapy areas. Key marketed products include treatments for heart failure, hypertension, and related cardiovascular conditions, alongside respiratory medicines and products addressing acute obstetric and gynaecological needs. Rather than pursuing early-stage drug discovery, Covis focuses on lifecycle management and ensuring continued patient access to medicines that retain clinical relevance. Covis operates through direct commercial infrastructure in multiple European markets and partners with distributors and co-promotion arrangements where its own footprint does not reach. The company has grown substantially through a series of portfolio acquisitions from major pharmaceutical groups, adding assets that benefit from dedicated commercial attention rather than competing for resources within large multinational pipelines. The business is privately held and backed by Apollo Global Management, which has supported its acquisition-led growth strategy. This structure allows Covis to move with relative speed on asset deals and to take a long-term view on branded generics and mature specialty products that still address unmet patient needs in their therapeutic categories. Further information is available at covispharma.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy